Skip to content
OpenCapital
Get started

Amphastar Pharmaceuticals AMPH Debt Issuance Cost Amortization

Debt Issuance Cost Amortization at other companies

Opko Health logo
Opko HealthOPK
$137K-68.1%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$3.89M-42.9%
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
$2.82M+2.4%
HRO
HarrowHROW
$451K-64.6%

Other financials

Income statement

See full
Revenue$171.2M+0.4%
Gross profit$70.3M-17.5%
Operating income$13.6M-63.5%
Net income$6.4M-74.6%
EPS (diluted)$0.14-72.5%

Balance sheet

See full
Cash & equivalents$170.9M-6.5%
Total debt$686.6M+5.2%
Total equity$445.5M—
Total assets$1.6B+1.3%

Cash flow

See full
Operating cash flow$47.8M+36.4%
CapEx$9.5M-11.1%
Free cash flow$38.3M+57.2%

Valuation

See full
Market cap$927.72M-19.9%
Enterprise value$1.44B-11.3%
P/E11.7×+3.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin47.3%-3.2pp
Operating margin16.2%-10.4pp
Net margin11%-8.4pp
FCF margin18.8%-1.8pp

Returns & leverage

See full
Return on equity14.7%—
Debt / equity0.2×—
Current ratio3.9×+0.9×

Where this comes from

Reported directly by Amphastar Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amphastar Pharmaceuticals's debt issuance cost amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amphastar Pharmaceuticals's debt issuance cost amortization?
Amphastar Pharmaceuticals (AMPH) reported debt issuance cost amortization of $761K in Q1 2026.
How has Amphastar Pharmaceuticals's debt issuance cost amortization changed year-over-year?
Amphastar Pharmaceuticals's debt issuance cost amortization decreased by 0.1% year-over-year, from $762K to $761K.
What is the long-term trend for Amphastar Pharmaceuticals's debt issuance cost amortization?
Over 3 years (2021 to 2025), Amphastar Pharmaceuticals's debt issuance cost amortization has grown at a 148.4% compound annual growth rate (CAGR), from $219K to $3.36M.
What does debt issuance cost amortization mean?
Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).